News

MediciNova's MN-166 Abstract Accepted for NEALS 2024 Meeting

MediciNova's MN-166 Abstract Accepted for NEALS 2024 Meeting

MediciNova Achieves a Major Milestone with MN-166

MediciNova, Inc., located in La Jolla, California, has recently reached an important milestone that paves the way for advancements in the treatment of neurodegenerative diseases. The company announced that an abstract related to its clinical trial of MN-166, also known as ibudilast, has been accepted for presentation at the upcoming Annual NEALS Meeting. This event will gather experts in amyotrophic lateral sclerosis (ALS), giving MediciNova a valuable opportunity to present its cutting-edge research.

Overview of the COMBAT-ALS Clinical Trial

The COMBAT-ALS Phase 2b/3 trial of MN-166 is a vital study designed to assess the efficacy and safety of this medication in patients suffering from ALS. The details of the trial will be presented in a poster format on October 23, 2024, by Dr. Björn Oskarsson, an important contributor to this research and an Associate Professor of Neurology. This presentation highlights MediciNova's dedication to improving treatment options for ALS patients.

Details of the Presentation

The accepted abstract will address key components of the trial. Here are some important details:

  • Submission ID: 164
  • Title: COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update
  • Session: Poster Presentation
  • Date: October 23, 2024

Exploring MN-166 (Ibudilast)

MN-166 is a small molecule compound recognized for its function as a phosphodiesterase type-4 (PDE4) inhibitor, along with its capacity to modulate inflammatory cytokines. This drug is currently in late-stage clinical development not just for ALS, but also for various other conditions including progressive multiple sclerosis, degenerative cervical myelopathy, glioblastoma, and long COVID. Its diverse mechanisms of action position it as a promising candidate in the field of neurodegenerative therapies.

About MediciNova, Inc.

MediciNova is committed to creating innovative therapies that target inflammatory, fibrotic, and neurodegenerative conditions. The company has a broad pipeline of clinical programs, led by its primary compound, MN-166, which is advancing through Phase 3 trials aimed at both ALS and degenerative cervical myelopathy. Additionally, MN-001 (tipelukast) is included in their pipeline and is currently being developed for metabolic-associated fatty liver disease.

With a robust foundation in clinical research, MediciNova is well-equipped to drive multiple initiatives that have the potential for significant impact. Their unwavering focus on patient care and innovative scientific approaches continues to propel the company's achievements.

Frequently Asked Questions

What is the significance of the NEALS meeting?

The NEALS meeting is a prestigious event that showcases the latest research in ALS and related areas, providing a platform for experts to exchange findings and advancements.

What is MN-166 used for?

MN-166 is primarily being studied for its effects on neurodegenerative diseases, including ALS, progressive multiple sclerosis, and other related conditions.

Who is presenting the MN-166 abstract?

The abstract regarding the MN-166 clinical trial will be presented by Dr. Björn Oskarsson, a distinguished Associate Professor of Neurology.

What stage is MN-166 currently in for ALS treatment?

MN-166 is currently undergoing Phase 3 clinical trials for ALS, indicating that it has made significant progress in its development.

Where can I learn more about MediciNova?

To find more information about MediciNova, including their initiatives and contact details, you can visit their official website or reach out via email.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Timur Turlov Leads FIDE with Chess and Digital Focus

Updated Category News Views 3

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 3

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 5

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 3

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 7

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 3

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 5

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 3

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading

Top 5 Most Recently Viewed Articles

BioLineRx Strengthens Market Position with New Cancer Drug Patent

Updated Category News Views 54

BioLineRx Secures a Crucial Patent for Motixafortide BioLineRx Ltd. (NASDAQ:TASE: BLRX), a biopharmaceutical company dedicated to oncology and rare diseases, has made significant strides in its efforts to protect its innovative cancer drug, motixafortide. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office, granting a new patent that...

Continue Reading
Exploring the Growing Ferulic Acid Market and Future Trends

Updated Category News Views 261

Global Ferulic Acid Market Outlook As the global market for ferulic acid continues to evolve, projections indicate a significant rise in value, moving from USD 207.7 million to USD 295.3 million in just a few years. By 2035, the market is expected to soar to USD 631.7 million, demonstrating a healthy compound annual growth rate (CAGR) of 7.9%. This growth can be...

Continue Reading
Hut 8 Corp Sees Major Gains Amid AI Center Developments

Updated Category News Views 148

Key Factors Behind Hut 8 Corp's Rising Stock Value Recently, shares of Hut 8 Corp. (NASDAQ: HUT) have been experiencing a notable upward trend. This surge can be attributed to several significant factors that have captured the attention of investors and analysts alike. Positive Analyst Ratings Fueling Investor Confidence Analysts are currently revising their ratings and...

Continue Reading
Canada Nickel Sells Lucas Project, Acquires Key Property

Updated Category News Views 8

Canada Nickel's Strategic Shuffle Somewhere along the line, you figure out what keeps the wheels turning in the resource game. For Canada Nickel, it looks like unloading some non-core baggage while doubling down on what really matters—the Crawford Nickel Project. On the chopping block is the Lucas Gold Project, now heading over to Noble Mineral Exploration. Meanwhile,...

Continue Reading
TotalEnergies Expands Investments in LNG and Renewable Energy

Updated Category News Views 352

TotalEnergies Ventures into LNG and Renewable Expansion TotalEnergies SE (NYSE: TTE) has recently made headlines as its shares rise following the company's strategic presentation in New York, showcasing an ambitious outlook for the future. The focus on a disciplined investment policy indicates the company's commitment to navigating the evolving energy landscape. Ambitious...

Continue Reading